

Press release
May 5, 2010
Gothenburg, Sweden

New CFO at Vitrolife

Anne-Lie Sveder has been appointed as the new Head of Vitrolife's Accounting and Finance department and Investor Relations. Anne-Lie Sveder is today working as a chartered accountant and director at accounting firm PricewaterhouseCoopers AB, mainly with companies which are related to the stock market and / or international activities.

Anne-Lie Sveder will assume her new position during the month of August and will then replace Eva Nilsagård, Vitrolife's CFO, who has decided to terminate her employment at Vitrolife. Eva will begin to work at Volvo Penta AB as Manager Parts & Accessories and Dealer Development, Region Europe. Eva Nilsagård will terminate her employment at Vitrolife in the end of August.

May 5, 2010
Gothenburg, Sweden
Magnus Nilsson, CEO

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 170 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Wednesday May 5, 2010 at 6.30 am.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.